Brain-Derived Neurotrophic Factor Gene Val66Met Polymorphism Modulates Reversible Cerebral Vasoconstriction Syndromes

Background: Reversible cerebral vasoconstriction syndrome (RCVS) could be complicated by cerebral ischemic events. Hypothetical mechanisms of RCVS involve endothelial dysfunction and sympathetic overactivity, both of which were reported to be related to brain-derived neurotrophic factor (BDNF). The study investigated the association between functional BDNF Val66Met polymorphism and RCVS. Methods: Patients with RCVS and controls were prospectively recruited and genotyped for the BDNF Val66Met polymorphism. Magnetic resonance angiography (MRA) and transcranial color-coded Doppler sonography were employed to evaluate cerebral vasoconstriction. Genotyping results, clinical parameters, vasoconstriction scores, mean flow velocities of the middle cerebral artery (V-MCA), and Lindegaard indices were analyzed. Split-sample approach was employed to internally validate the data. Principal Findings: Ninety Taiwanese patients with RCVS and 180 age-and gender-matched normal controls of the same ethnicity completed the study. The genotype frequencies did not differ between patients and controls. Compared to patients with Met/Met homozygosity, patients with Val allele had higher mean vasoconstriction scores of all arterial segments (1.60 +/- 0.72 vs. 0.87 +/- 0.39, p < 0.001), V-MCA values (116.7 +/- 36.2 vs. 82.7 +/- 17.9 cm/s, p < 0.001), and LI (2.41 +/- 0.91 vs. 1.89 +/- 0.41, p = 0.001). None of the Met/Met homozygotes, but 38.9% of the Val carriers, had V-MCA values of > 120 cm/s (p < 0.001). Split-sample validation by randomization, age, entry time or residence of patients demonstrated concordant findings. Conclusions: Our findings link BDNF Val66Met polymorphism with the severity of RCVS for the first time and implicate possible pathogenic mechanisms for vasoconstriction in RCVS.